TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38413930

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) plus basiliximab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Basiliximab alone (Control)
Number of subjects: 130
Study: 38413986

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 38413990

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MD-Int)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Regular health advice (RHA)
Number of subjects: 125
Study: 38413997

Group type: EXPERIMENTAL
Intervention: Prelacteal feeding (PLF)
Number of subjects: 3332

Group type: COMPARATOR
Intervention: No prelacteal feeding
Number of subjects: 3332
Study: 38414003

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation at 20 g/day
Number of subjects: 20
Study: 38414045

Group type: EXPERIMENTAL
Intervention: Videoconferencing genetic services (Arm A)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Phone genetic services (Arm B)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care services (Arm C)
Number of subjects: 360
Study: 38414067

Group type: EXPERIMENTAL
Intervention: Intravenous UC-MSC infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal UC-MSC infusion
Number of subjects: 0
Study: 38414126

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study: 38414426

Group type: EXPERIMENTAL
Intervention: Breast cancer surgery
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Sternotomy
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Endometriosis surgery
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: All types of surgery
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: CPSP
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Pre-operative pain
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Severe CPSP
Number of subjects: 3297
Study: 38414510

Group type: EXPERIMENTAL
Intervention: Tislelizumab immunotherapy
Number of subjects: 12
Study: 38414555

Group type: EXPERIMENTAL
Intervention: IA-tirofiban
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: IV-tirofiban
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: IA+IV-tirofiban
Number of subjects: 502

Group type: COMPARATOR
Intervention: non-tirofiban
Number of subjects: 502
Study: 38414563

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention over 4 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention
Number of subjects: 32
Study: 38414658

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) administration prior to photodynamic therapy (PDT)
Number of subjects: 13
Study: 38414886

Group type: EXPERIMENTAL
Intervention: Healthy eating and activity intervention embedded in a national home visiting program (Parents as Teachers)
Number of subjects: 276
Study: 38414923

Group type: EXPERIMENTAL
Intervention: SeQuent® crystalline sirolimus-coated balloon (SCB)
Number of subjects: 126
Study: 38415370

Group type: EXPERIMENTAL
Intervention: Elranatamab
Number of subjects: 123

Group type: COMPARATOR
Intervention: Physician's choice of treatment (PCT)
Number of subjects: 123
Study: 38415722

Group type: EXPERIMENTAL
Intervention: Radar-based home sleep apnea test (HSAT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single measurement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multiple measurements (5 measurements)
Number of subjects: 28
Study: 38415785

Group type: EXPERIMENTAL
Intervention: Enpatoran (100, 200, and 300 mg orally administered)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enpatoran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldehyde oxidase (AOX) function
Number of subjects: 0
Study: 38415895

Group type: EXPERIMENTAL
Intervention: Sirolimus drug coated balloon (DCB)
Number of subjects: 757
Study: 38416143

Group type: EXPERIMENTAL
Intervention: C-PRIME digital health promotion intervention
Number of subjects: 13
Study: 38416176

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 9
Study: 38416223

Group type: EXPERIMENTAL
Intervention: THC (8 mg THC for a 75-kg person)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: THC + CBD (8 mg THC and 24 mg CBD for a 75-kg person)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PLA (matched placebo)
Number of subjects: 48
Study: 38416237

Group type: EXPERIMENTAL
Intervention: Faricimab treatment
Number of subjects: 46
Study: 38416256

Group type: EXPERIMENTAL
Intervention: Automatic MRI segmentation using nnU-Net
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning classifier system for liver herniation prediction
Number of subjects: 0
Study: 38416313

Group type: EXPERIMENTAL
Intervention: Unplugged Program (intervention arm)
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Control group (non-intervention arm)
Number of subjects: 1874
Study: 38416391

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 102
Study: 38416398

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 1198
Study: 38416430

Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Radical hysterectomy
Number of subjects: 700
Study: 38416468

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waiting group after receiving 1-Hz rTMS
Number of subjects: 88
Study: 38416472

Group type: EXPERIMENTAL
Intervention: CT-first strategy
Number of subjects: 3561

Group type: COMPARATOR
Intervention: Direct-to-ICA strategy
Number of subjects: 3561
Study: 38416500

Group type: EXPERIMENTAL
Intervention: Hypothermia (34.0-35.0 °C)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Normothermia (36.5-37.5 °C)
Number of subjects: 509
Study: 38416544

Group type: EXPERIMENTAL
Intervention: Prototype sensor for swallowing monitoring
Number of subjects: 166
Study: 38416559

Group type: EXPERIMENTAL
Intervention: Screening and retention strategies using social media (Instagram)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Alternative communication methods (Instagram)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Direct messaging on Instagram
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Demographic data collection
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Other alternative means of contact (Facebook, alternative email)
Number of subjects: 1216
Study: 38416574

Group type: EXPERIMENTAL
Intervention: Digital weight gain prevention intervention (Balance)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 443
Study: 38416809

Group type: EXPERIMENTAL
Intervention: Systemic metformin (1000 mg/d) with TCA peeling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Systemic metformin (500 mg/d) with TCA peeling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with TCA peeling
Number of subjects: 60
Study: 38416811

Group type: EXPERIMENTAL
Intervention: Straight-Line (SL) closure
Number of subjects: 50

Group type: COMPARATOR
Intervention: W-plasty closure
Number of subjects: 50
Study: 38416865

Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil with Aripiprazole Lauroxil NanoCrystal Dispersion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone Palmitate Monthly
Number of subjects: 0
Study: 38417017

Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery System with Automatic Meal Bolus
Number of subjects: 0
Study: 38417039

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-alcohol consumers)
Number of subjects: 0
Study: 38417060

Group type: EXPERIMENTAL
Intervention: Vedolizumab IV induction therapy
Number of subjects: 994
Study: 38417209

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Predictive index model (PIV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 50
Study: 38417207

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Intervention Package (CBIP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Routine PVC procedure (Control)
Number of subjects: 77
Study: 38417221

Group type: EXPERIMENTAL
Intervention: ESC 0/1-h high sensitivity troponin T (hs-cTnT) algorithm
Number of subjects: 1430
Study: 38417277

Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) 1050 mg BID (FBS capsule) or 750 mg BID (SDD tablet)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) with tumor testing
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) with ctDNA testing
Number of subjects: 68
Study: 38417400

Group type: EXPERIMENTAL
Intervention: Fatigue Self-Management Program
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 94
Study: 38417440

Group type: EXPERIMENTAL
Intervention: Single-dose camrelizumab alone (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microwave ablation alone (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Camrelizumab + Microwave ablation (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 38417549

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMs) (15 micronutrients including IFA)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) only
Number of subjects: 1599
Study: 38417552

Group type: EXPERIMENTAL
Intervention: Synthetic hygroscopic dilators
Number of subjects: 174

Group type: COMPARATOR
Intervention: 30-mL silicone single-balloon catheter
Number of subjects: 174
Study: 38417773

Group type: EXPERIMENTAL
Intervention: Trans-nasal cooling within 20 minutes from EMS arrival followed by in-hospital hypothermia at 33°C for 24 hours
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Standard of care with no prehospital or in-hospital cooling
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Trans-nasal cooling
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1022
Study: 38417976

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus rilpivirine (50 mg dolutegravir plus 25 mg rilpivirine once daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (current antiretroviral therapy regimen)
Number of subjects: 140
Study: 38418002

Group type: EXPERIMENTAL
Intervention: Routine functional testing at 1 year
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1192
Study: 38418004

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 5661

Group type: COMPARATOR
Intervention: ramipril
Number of subjects: 5661

Group type: COMPARATOR
Intervention: sacubitril/valsartan vs ramipril
Number of subjects: 5661
Study: 38418209

Group type: EXPERIMENTAL
Intervention: Gestational age 34-35 weeks
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Gestational age 37-38 weeks
Number of subjects: 794

Group type: COMPARATOR
Intervention: Gestational age 39-40 weeks
Number of subjects: 794
Study: 38418234

Group type: EXPERIMENTAL
Intervention: Camrelizumab in combination with chemotherapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study: 38418236

Group type: EXPERIMENTAL
Intervention: Internet of Things (IoT) management model
Number of subjects: 682
Study: 38418244

Group type: EXPERIMENTAL
Intervention: Mental health comorbidity in patients with IBD
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Mental health comorbidity in patients with IBD aged ≥18 years
Number of subjects: 1943
Study: 38418306

Group type: EXPERIMENTAL
Intervention: In-hospital major adverse events (MAE)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Length of ICCU hospitalization
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Advanced ICCU therapies
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Invasive procedures
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Cardiac imaging
Number of subjects: 1499
Study: 38418343

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (EV)
Number of subjects: 608
Study: 38418350

Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MDS)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) score
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Plant-based diet indices (PDIs)
Number of subjects: 765
Study: 38418384

Group type: EXPERIMENTAL
Intervention: Usual care with remote digital monitoring of home spirometry and pulse oximetry
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 132
Study: 38418563

Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa + miglustat (cipa + mig)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Alglucosidase alfa + placebo (alg + pbo)
Number of subjects: 118
Study: 38418863

Group type: EXPERIMENTAL
Intervention: bioactive ionic resin composite (Activa Bioactive Base/Liner)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: resin-modified glass ionomer liner (Riva Light Cure)
Number of subjects: 20
Study: 38418879

Group type: EXPERIMENTAL
Intervention: Tiragolumab (anti-TIGIT antibody) combined with atezolizumab (anti-PD-L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1) alone
Number of subjects: 0
Study: 38418982

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA) paediatric granules, administered once daily for 3 days
Number of subjects: 667

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL), comparator in two trials
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: CANTAM study with PA
Number of subjects: 667
Study: 38419024

Group type: EXPERIMENTAL
Intervention: 12-week exercise therapy and education (ExE) and 10-module internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TKA followed by ExE and iCBT
Number of subjects: 15

Group type: COMPARATOR
Intervention: TKA and standard postoperative care
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall recruitment and retention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Compliance to iCBT
Number of subjects: 15
Study: 38419030

Group type: EXPERIMENTAL
Intervention: Stereotactically guided intracerebral injection of CTX0E03, a fetal derived neural stem cell line.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hybrid recruitment approach using a patient-facing web portal for initial screening and subsequent phone and medical record review.
Number of subjects: 86
Study: 38419032

Group type: EXPERIMENTAL
Intervention: Compressive Cryotherapy (CC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Cryotherapy (SC)
Number of subjects: 40
Study: 38419035

Group type: EXPERIMENTAL
Intervention: eclitasertib 600 mg (300 mg twice daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 38419049

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard emergency care
Number of subjects: 0
Study: 38419058

Group type: EXPERIMENTAL
Intervention: OMIE approach along with dissemination of OEND best practice recommendations
Number of subjects: 105

Group type: COMPARATOR
Intervention: Dissemination of OEND best practice recommendations (Control SSPs)
Number of subjects: 105
Study: 38419068

Group type: EXPERIMENTAL
Intervention: Low-calorie chronotype-adapted diet
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standardized low-calorie healthy eating plan
Number of subjects: 150
Study: 38419075

Group type: EXPERIMENTAL
Intervention: VEERALIN® LN (PBO-py)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interceptor® G2 LN (chlorfenapyr-py)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MAGNet® LN (control, py)
Number of subjects: 50
Study: 38419119

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 333
Study: 38419131

Group type: EXPERIMENTAL
Intervention: Laboratory-based PCR viral testing
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Point-of-care antigen testing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both testing protocols (LAB and POC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Concern for contracting COVID-19
Number of subjects: 72
Study: 38419156

Group type: EXPERIMENTAL
Intervention: COVID-19-associated invasive fungal infections (CAIFIs)
Number of subjects: 276

Group type: COMPARATOR
Intervention: No CAIFIs
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: CAIFIs
Number of subjects: 276
Study: 38419159

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38419215

Group type: EXPERIMENTAL
Intervention: Saddle-contoured metal matrix (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pre-contoured self-adhesive matrix (Group B)
Number of subjects: 60
Study: 38419216

Group type: EXPERIMENTAL
Intervention: Positional release technique (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Myofascial release technique (Group B)
Number of subjects: 64
Study: 38419600

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 13
Study: 38419648

Group type: EXPERIMENTAL
Intervention: Fasudil (two dosages)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 38419711

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 71
Study: 38419787

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg and 25 mg pooled doses)
Number of subjects: 6967

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6967
Study: 38419834

Group type: EXPERIMENTAL
Intervention: Total salt consumption (TS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discretionary salt (DS) consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bouillon contribution to total salt consumption
Number of subjects: 0
Study: 38419905

Group type: EXPERIMENTAL
Intervention: VR-assisted cognitive behavioral therapy (VR-CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CBT)
Number of subjects: 10
Study: 38419981

Group type: EXPERIMENTAL
Intervention: Low suction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intraoral suction (IOS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High & low suction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extra-oral suction (EOS) & low suction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IOS & EOS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (low or intraoral suction only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of suction devices (extra-oral with intra-oral suction, or extra-oral suction with low suction, or high & low suction)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Particulate matter
Number of subjects: 50
Study: 38420037

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Current obesity
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: High cholesterol
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4800
Study: 38420117

Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paper-based instructions
Number of subjects: 60
Study: 38420260

Group type: EXPERIMENTAL
Intervention: Untreated viremic participants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Participants virologically controlled on ART
Number of subjects: 20
Study: 38420356

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) injection with evidence-based treatment rationale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-time 'Booster' group with one single repetition of the OLP injection at a fixed time point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-demand 'Booster' group with one single repetition of the OLP injection on-demand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving just one OLP injection
Number of subjects: 0
Study: 38420657

Group type: EXPERIMENTAL
Intervention: elranatamab (12 mg on day 1, 32 mg on day 4, 76 mg on day 8, each cycle = 28 days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: elranatamab
Number of subjects: 187
Study: 38420809

Group type: EXPERIMENTAL
Intervention: Collagen-related cell adhesion molecules (CAMs) identified through multi-omics data analysis and bioinformatics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor tissue and para-cancerous tissue samples from HCC patients validated using RT-PCR.
Number of subjects: 0
Study: 38420848

Group type: EXPERIMENTAL
Intervention: Forced-rate aerobic exercise (FE) paired with upper extremity repetitive task practice (RTP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RTP only
Number of subjects: 60
Study: 38420947

Group type: EXPERIMENTAL
Intervention: Remote training (RT group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-study (SS group)
Number of subjects: 23